The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Pharmaceutical operations remain central to large-cap healthcare discussions Balance sheet positioning frames institutional comparisons Broader sentiment reflects themes seen in s&p 500 chart Pfizer ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...